Anastrozole
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1995
- First approval year
- 1995
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Anastrozole
- Molecular weight
- 293.37
- Structure (SMILES)
- CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1
- anastrozole
- Anastrozole
- arimidex
- Arimidex
- nastrosa
- Nastrosa
- 1 3 benzenediacetonitrile alpha alpha alpha alpha tetramethyl 5 1h 1 2 4 triazol 1 ylmethyl
- 1,3-BENZENEDIACETONITRILE,.ALPHA.,.ALPHA.,.ALPHA.',.ALPHA.'-TETRAMETHYL-5-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-
- abemaciclib and letrozole anastrozole
- Anastozole (Arimidex)
- Anastrazole (Arimidex)
- anastrazole (Arimidex®)
- anastrozol
- Anastrozol
- anastrozole
- Anastrozole
- anastrozole (Arimidex)
- Anastrozole (Arimidex)
- Anastrozole (Arimidex®)
- Anastrozole (ARIMIDEX™)
- Anastrozole (Aromatase Inhibitor)
- Anastrozole (Teva Pharmaceuticals USA)
- ANASTROZOLE [EP MONOGRAPH]
- ANASTROZOLE [HSDB]
- anastrozole [INN]
- ANASTROZOLE [JAN]
- ANASTROZOLE [MART.]
- ANASTROZOLE [MI]
- ANASTROZOLE [ORANGE BOOK]
- ANASTROZOLE [USAN]
- ANASTROZOLE [USP IMPURITY]
And 44 more, listed on the interactive page.
- ATC classification codes
- L02BG03
Sources for recorded values
- CAS registry numbers
- 120511-73-1
- ChEMBL ID
- CHEMBL1399
- InChIKey
- YBBLVLTVTVSKRW-UHFFFAOYSA-N
- PubChem compound IDs
- 2187
- RxNorm IDs (RxCUI)
- 84857
- FDA ingredient codes (UNII)
- 2Z07MYW1AZ
- Applicant
- ANI PHARMS
- Approval date
- 27 Dec 1995
- Application number
- NDA020541
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
- Pharmacology name
- anastrozole
- Type
- Synthetic organic
- Drug name stem
- -rozole
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- CYP19A1
- Gene symbol
- CYP19A1
- Protein identifier
- P11511
- Median affinity
- 7.82
- Affinity units
- pIC50
- Primary target
- Yes
- Mechanism
- Cytochrome P450 19A1 inhibitor
- Action type
- Inhibitor
- Target
- Aromatase
- Protein identifier
- P11511
Open Targets mechanisms
- Mechanism
- Cytochrome P450 19A1 inhibitor
- Action type
- Inhibitor
- Target
- Aromatase
DrugCentral mechanisms
- Action type
- Inhibitor
- Gene symbol
- CYP19A1
- Protein identifier
- P11511
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Metabolic Syndrome
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000195
- Subject identifier
- D024821
- Condition
- Breast Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000305
- Subject identifier
- D001943
- Condition
- Carcinoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000313
- Subject identifier
- D002277
- Condition
- Carcinoma, Intraductal, Noninfiltrating
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000432
- Subject identifier
- D002285
- Condition
- Hypertension
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0000537
- Subject identifier
- D006973
- Condition
- Carcinoma, Lobular
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000553
- Subject identifier
- D018275
- Condition
- Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Endometriosis
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001065
- Subject identifier
- D004715
- Condition
- Hypertension, Pulmonary
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001361
- Subject identifier
- D006976
- Condition
- Hypopituitarism
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001380
- Subject identifier
- D007018
- Condition
- Breast Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003869
- Subject identifier
- D001943
- Condition
- Triple Negative Breast Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005537
- Subject identifier
- D064726
- Condition
- Breast Neoplasms, Male
- Highest recorded phase
- 2
- Condition identifier
- EFO:0006861
- Subject identifier
- D018567
- Condition
- Breast Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0009483
- Subject identifier
- D001941
- Condition
- Aging
- Highest recorded phase
- 1
- Condition identifier
- EFO:0022597
- Subject identifier
- D000375
- Condition
- Klinefelter Syndrome
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001006
- Subject identifier
- D007713
- Condition
- Endometrial Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:1001512
- Subject identifier
- D016889
- Condition
- Gynecomastia
- Highest recorded phase
- 3
- Condition identifier
- HP:0000771
- Subject identifier
- D006177
- Condition
- Puberty, Precocious
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0000088
- Subject identifier
- D011629
- Condition
- Hypogonadism
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0002146
- Subject identifier
- D007006
- Condition
- Anovulation
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0002775
- Subject identifier
- D000858
- Condition
- Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0004992
- Subject identifier
- D009369
- Condition
- Breast Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0007254
- Subject identifier
- D001943
- Condition
- Ovarian Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0008170
- Subject identifier
- D010051
- Condition
- Endometrial Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0011962
- Subject identifier
- D016889
And 3 more, listed on the interactive page.
- Condition identifier
- EFO_0000195
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000305
- Condition identifier
- EFO_0000313
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000432
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000537
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0001065
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001361
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003869
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004714
- Highest recorded phase
- 2
- Condition identifier
- EFO_0009483
- Condition identifier
- EFO_0009870
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000307
- Condition identifier
- EFO_1001006
- Highest recorded phase
- 3
- Condition identifier
- HP_0000771
- Highest recorded phase
- 3
- Condition identifier
- HP_0000789
- Highest recorded phase
- 3
- Condition identifier
- HP_0000855
- Highest recorded phase
- 2
- Condition identifier
- HP_0002829
- Condition identifier
- HP_0012743
- Condition identifier
- MONDO_0000088
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002146
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002447
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004379
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004953
- Condition identifier
- MONDO_0004989
- Highest recorded phase
- 4
And 31 more, listed on the interactive page.
- Event
- alopecia
- Reports
- 639
- Reporting signal score
- 501.004
- Event
- arthralgia
- Reports
- 1,387
- Reporting signal score
- 766.594
- Event
- bone pain
- Reports
- 484
- Reporting signal score
- 555.235
- Event
- breast cancer
- Reports
- 743
- Reporting signal score
- 1,384.6
- Event
- breast cancer metastatic
- Reports
- 702
- Reporting signal score
- 2,425.01
- Event
- breast cancer recurrent
- Reports
- 220
- Reporting signal score
- 663.174
- Event
- carbohydrate antigen 15-3 increased
- Reports
- 97
- Reporting signal score
- 362.44
- Event
- carpal tunnel syndrome
- Reports
- 53
- Reporting signal score
- 84.4647
- Event
- disease progression
- Reports
- 797
- Reporting signal score
- 790.879
- Event
- fatigue
- Reports
- 1,443
- Reporting signal score
- 266.103
- Event
- hot flush
- Reports
- 580
- Reporting signal score
- 830.111
- Event
- malignant neoplasm progression
- Reports
- 1,690
- Reporting signal score
- 3,447.45
- Event
- metastases to bone
- Reports
- 932
- Reporting signal score
- 2,763.91
- Event
- metastases to liver
- Reports
- 747
- Reporting signal score
- 2,063.58
- Event
- metastases to lung
- Reports
- 363
- Reporting signal score
- 887.657
- Event
- metastases to lymph nodes
- Reports
- 274
- Reporting signal score
- 702.82
- Event
- metastases to skin
- Reports
- 85
- Reporting signal score
- 255.825
- Event
- metastases to spine
- Reports
- 119
- Reporting signal score
- 319.107
- Event
- nasal disorder
- Reports
- 30
- Reporting signal score
- 77.7688
- Event
- neoplasm progression
- Reports
- 787
- Reporting signal score
- 1,695.49
- Event
- neutropenia
- Reports
- 1,377
- Reporting signal score
- 1,390.24
- Event
- osteopenia
- Reports
- 58
- Reporting signal score
- 106.355
- Event
- pik3ca-activated mutation
- Reports
- 95
- Reporting signal score
- 399.89
- Event
- tonsillar disorder
- Reports
- 28
- Reporting signal score
- 87.7008
- Event
- trigger finger
- Reports
- 44
- Reporting signal score
- 125.292
And 1 more, listed on the interactive page.
- NCT00004900
- NCT00004906
- NCT00005908
- NCT00049062
- NCT00053898
- NCT00053911
- NCT00057941
- NCT00066378
- NCT00066573
- NCT00072462
- NCT00075764
- NCT00077025
- NCT00077168
- NCT00078832
- NCT00081510
- NCT00082277
- NCT00126360
- NCT00128843
- NCT00186121
- NCT00206414
- NCT00217399
- NCT00217659
- NCT00232661
- NCT00235937
- NCT00244959
And 178 more, listed on the interactive page.
- Dose
- 1mg
- Route
- Oral
- How often
- Once daily
Conditions of use
- Take with or without food
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 0
- Polar surface area
- 78.29
- Calculated partition coefficient (ALogP)
- 2.93
- Calculated partition coefficient (XLogP)
- 2.1
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 4
- Heavy atoms
- 22
- Molecular formula
- C17H19N5
- Monoisotopic mass
- 293.16404563
- Natural product
- Yes
- 0093-7536
- 16729-035
- 23155-857
- 24979-725
- 42291-016
- 42291-085
- 43063-383
- 50268-075
- 51991-620
- 59651-236
- 60687-112
- 62135-490
- 62559-670
- 63187-080
- 65841-743
- 68001-155
- 68382-209
- 72189-415
- 72189-682
- 72789-008
- 72789-342
- 72789-575
- 76420-004
- 82804-162
- 87063-224
And 15 more, listed on the interactive page.
- Recorded assays
- 3,012
- Active assays
- 52
- Confirmatory
- Other
- Screening
- Summary
- Antineoplastic Agents, Hormonal
- Aromatase Inhibitors
Oral bioavailability
- Median
- 84
- Mean
- 84
- Minimum
- 84
- Maximum
- 84
- Unit
- %
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Related records
Trials (303)
- 3 Years of Anastrozole vs. no Treatment as Extended Adjuvant Therapy for Postmenopausal Women With Breast Cancer
- A Clinical Study of Darcilil Combined With AI Combined With Pyrrotinib in the Treatment of TPBC
- A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer
- A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
- A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.
- A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer
- A Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
- A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
- A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer
- A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
- A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors
- A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer
- A Prospective,Open-label Study of Anastrozole in Post-menopausal Women With Hormone Sensitive Advanced Breast Cancer
- A Retrospective Real-world Study of Abemaciclib in HR+ Breast Cancer
- A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer
- A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
- A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer
- A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
- A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
- A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Approved for (5)
- Breast cancer
- Breast carcinoma
- Breast neoplasm
- Cancer
- Neoplasm
In development for (23)
- Anovulation Phase 2
- Breast disorder Phase 1
- Carcinoma Phase 2
- Ductal breast carcinoma in situ Phase 3
- Endometrial cancer Phase 1
- Endometrial carcinoma Phase 1
- Endometriosis Phase 2
- Female breast carcinoma Phase 3
- Gynecomastia disorder Phase 3
- Hypertensive disorder Early phase 1
- Hypogonadism Phase 2
- Hypogonadotropic hypogonadism Phase 2
- Hypopituitarism Phase 2
- Invasive lobular breast carcinoma Phase 3
- Kallmann syndrome Phase 1
- Klinefelter syndrome Phase 3
- Male breast carcinoma Phase 2
- McCune-Albright syndrome Phase 2
- Metabolic syndrome X Phase 2
- Ovarian cancer Phase 3
Other linked conditions (1)
- Invasive breast carcinoma
Targets (1)
- CYP19A1 Cytochrome P450 19A1 inhibitor